A previous study reported that small interfering RNAs (siRNAs) against CCR2 delivered in lipid nanoparticles can experimentally reduce myocardial infarct size in mouse model of myocardial ischemia reperfusion11, suggesting the feasibility of targeting CCR2+ inflammatory monocytes; however, chemicals including irbesartan possess superior stability to siRNA especially in vivo, raising the possibility of clinical development. The gene discussed is CCR2; the disease is myocardial infarction.